论文部分内容阅读
为探讨改良的ＶＡＤ 方案与标准ＭＰ 方案治疗多发性骨髓瘤Ⅲ期的疗效差别，将４０ 例患者随机分成两组，分别予改良的ＶＡＤ 方案和标准ＭＰ 方案治疗。结果：改良ＶＡＤ 方案组的ＣＲ 率达３０ ％ ，ＰＲ 率达５０ ％ ，总有效率达８０ ％ ；而标准ＭＰ 方案组ＣＲ 率达１０ ％ ，ＰＲ 率达５０ ％ ，总有效率达６０ ％ 。两组比较差异有显著性（ Ｐ ＜ ０ ．０５） 。认为改良ＶＡＤ 方案治疗多发性骨髓瘤Ⅲ期病人效果优于标准ＭＰ 方案。
To investigate the difference in efficacy between the modified VAD regimen and the standard MP regimen in the treatment of multiple myeloma stage III, 40 patients were randomly divided into two groups, treated with modified VAD regimen and standard MP regimen, respectively. Results: The improved VAD protocol group had a CR rate of 30%, a PR rate of 50%, and a total effective rate of 80%. The standard MP program group had a CR rate of 10%, a PR rate of 50%, and a total effective rate of 60%. The difference between the two groups was significant (P < 0.05). It is believed that the improved VAD regimen is superior to the standard MP regimen in the treatment of multiple myeloma stage III patients.